glp 1 cpt code obesitymedicine #medicare #glp1 #patientaccess #priorauthorization | Joseph Zucchi, PA-C, MPAS Breast implant explantation with mastopexy
Description
Risk for DKA with SGLT2 inhibitor use is a key reason this class of medications has not yet been approved for use in type 1 diabetes in the United States
November 2023 : Eli Lilly received US FDA approval for ZEPBOUND, an obesity treatment that activates GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) hormone receptors
Not ideal for a drug that should be taken continuously, because the pounds pile back on quickly
2026 Feb;124:106119
